Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 32, Issue 4, 2007, Pages 233-240

  Natsui, Kiyohi ^a   Mizuno, Yoshiko ^a   Tani, Naoko ^a   Yabuki, Masashi ^a   Komuro, Setsuko ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

CYP2D6; CYP3A4; Human liver microsomes; In vitro metabolism; Tandospirone

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; KETOCONAZOLE; QUINIDINE; TANDOSPIRONE;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME;

EID: 39449136299     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191009     Document Type: Article

References (25)

1. Shimizu H., Karai N., Hirose A., Tatsuno T., Tanaka H., Kumasaka Y., Nakamura M. (1988): Interaction of SM-3997 with serotonin receptors in rat brain. Jpn J. Pharmacol., 46, 311-314.
2. Shimizu H., Hirose A., Tatsuno T., Nakamura M., Katsube J. (1987): Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn J. Pharmacol., 45, 493-500.
3. Kikuchi T., Goto Y., Suzuki J., Nagata H., Maeda S., Kanemoto S. (1992): Double-blind study of tandospirone (SM-3997) on essential hypertension as meaning of cardiovascular psychosomatic disease - Comparative study with diazepam. Clin. Rep., 26, 4351-4367.
4. 1A agonist (tandospirone). Jpn J. Psychopharmacol., 17, 53-59.
5. Mizuno Y., Iba K., Nakatsuka I., Yoshitake A. (1992): Absorption, distribution and excretion of SM-3997 in rats. Clin. Rep., 26, 1863-1883.
6. Mizuno Y., Iba K., Nakatsuka I., Yoshitake A. (1992): Metabolism of SM-3997. Clin. Rep., 26, 1885-1901.
7. Jones H.M., Houston J.B. (2004): Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos., 32, 973-982.
8. Hutzler J.M., Walker G.S., Wienkers L.C. (2003): Inhibition of cytochrome P450 2D6: structure activity studies using a series of quinidine and quinine analogues. Chem. Res. Toxicol., 16, 450-459.
9. Patki K.C., Von Moltke L.L., Greenblatt D.J. (2003): In vitro metabolism of midazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos., 31, 938-944.
10. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. (1994): Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423.
11. Rodríguez-Antona C., Donato M.T., Boobis A., Edwards R. J., Watts P.S., Castell J.V., Gómez-Lechón M.J. (2002): Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica, 32, 505-520.
12. Niwa T., Shiraga T., Ishii I., Kagayama A., Takagi A. (2005): Contribution of human hepatic cytochrome P450 isoforms to the metabolism of psychotropic drugs. Biol. Pharm. Bull., 28, 1711-1716.
13. Lamberg T.S., Kivistöo K.T., Neuvonen P.J. (1999): Lack of effects of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone. Pharmacol. Toxicol., 84, 165-169.
14. Laine K., Ahokoski O., Huupponen R., Hänninen J., Palovaara S., Ruuskanen J., Björklund H., Anttila M., Rouru J. (2003): Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Eur. J. Clin. Pharmacol., 59, 761-766.
15. Zhu M., Zhao W., Jimenez H., Zhang D., Yeola S., Dai R., Vachharajani N., Mitroka J. (2005): Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos., 33, 500-507.
16. von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Fogelman S.M., Harmatz J.S., Kramer S.J., Fabre L.F., and Shader R.I., (1998): Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. Psychopharmacology, 140, 293-299.
17. Greenblatt D.J., Von Moltke L.L., Giancarlo G.M., Garteiz D.A. (2003): Human cytochromes mediating gepirone biotransformation at low substrate concentrations. Biopharm. Drug Dispos., 24, 87-94.
18. Caccia S. (2004): Metabolism of the newest antidepressants: comparisons with related predecessors. Drugs, 7, 143-150
19. Kivistö K.T., Lamberg T.S., Kantola T., Neuvonen P.J. (1997): Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther., 62, 348-354.
20. Lamberg T.S., Kivistö K.T., Laitila J., Martensson K., Neuvonen P.J. (1998): The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur. J. Clin. Pharmacol., 54, 761-766.
21. Lilja J.J., Kivistö K.T., Backman J.T., Lamberg T.S., Neuvonen P.J. (1998): Grapefruit juice substantially increases plasma concentrations of buspirone. Clin. Pharmacol. Ther., 64: 655-660.
22. Lamberg T.S., Kivistö K.T., Neuvonen P.J. (1998): Concentrations and effects of buspirone are considerably reduced by rifampicin. Br. J. Clin. Pharmacol., 45, 381-385.
23. Kivistö K.T., Lamberg T.S., Neuvonen P.J. (1999): Interactions of buspirone with itraconazole and rifampicin effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacol. Toxicol., 84, 94-97.
24. Masui T., Kusumi I., Takahashi Y., Koyama T. (2006): Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther. Drug. Monit., 28, 73-75.
25. Kitamura A., Mizuno Y., Natsui K., Yabuki M., Komuro S., Kanamaru H. (2005): Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm. Drug Dispos., 26: 59-65.